All Stories

  1. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment

    Article • Journal of Antimicrobial Chemotherapy, March 2023, Oxford University Press (OUP)

    Wright Nichols

  2. The primary pharmacology of ceftazidime/avibactam: resistancein vitro

    Article • Journal of Antimicrobial Chemotherapy, January 2023, Oxford University Press (OUP)

    Wright Nichols

  3. The primary pharmacology of ceftazidime/avibactam: in vitro translational biology

    Article • Journal of Antimicrobial Chemotherapy, June 2022, Oxford University Press (OUP)

    Wright Nichols

  4. The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)

    Article • Journal of Antimicrobial Chemotherapy, June 2022, Oxford University Press (OUP)

    Wright Nichols

  5. Evaluation of the post-antibiotic effect in vivo for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections

    Article • Journal of Chemotherapy, March 2021, Taylor & Francis

    Wright Nichols

  6. Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

    Article • European Journal of Clinical Pharmacology, December 2019, Springer Science + Business Media

    Wright Nichols

  7. A model-based analysis of pharmacokinetic–pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa

    Article • Clinical Microbiology and Infection, July 2019, Elsevier

    Wright Nichols

  8. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

    Article • Antimicrobial Agents and Chemotherapy, April 2019, ASM Journals

    Wright Nichols

  9. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis

    Article • International Journal of Antimicrobial Agents, November 2018, Elsevier

    Wright Nichols

  10. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae

    Article • Journal of Antimicrobial Chemotherapy, September 2018, Oxford University Press (OUP)

    Wright Nichols

  11. Ceftazidime-Avibactam Susceptibility Breakpoints againstEnterobacteriaceaeandPseudomonas aeruginosa

    Article • Antimicrobial Agents and Chemotherapy, July 2018, ASM Journals

    Wright Nichols

  12. Understanding the pharmacodynamics of a clinically-used β-lactamase inhibitor, avibactam

    Article • Antimicrobial Agents and Chemotherapy, April 2018, ASM Journals

    Wright Nichols

  13. A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa

    Article • Journal of Antimicrobial Chemotherapy, February 2018, Oxford University Press (OUP)

    Wright Nichols

  14. Ceftazidime-avibactam against a KPC-2 β-lactamase producing Klebsiella pneumoniae in vivo

    Article • Journal of Chemotherapy, November 2017, Taylor & Francis

    Wright Nichols

  15. AmpC β-lactamase induction by avibactam and relebactam

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Wright Nichols

  16. Understanding the penetration of potential novel antibiotics into bacteria

    Article • Antimicrobial Agents and Chemotherapy, July 2017, ASM Journals

    Wright Nichols

  17. The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil

    Article • The Brazilian Journal of Infectious Diseases, April 2017, Elsevier

    Wright Nichols

  18. Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations

    Article • International Journal of Antimicrobial Agents, April 2017, Elsevier

    Wright Nichols

  19. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms ofPseudomonas aeruginosa

    Article • Journal of Antimicrobial Chemotherapy, January 2017, Oxford University Press (OUP)

    Wright Nichols

  20. Potentiation of ceftazidime by avibactam against β-lactam-resistantPseudomonas aeruginosain anin vitroinfection model

    Article • Journal of Antimicrobial Chemotherapy, January 2017, Oxford University Press (OUP)

    Wright Nichols

  21. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain

    Article • Diagnostic Microbiology and Infectious Disease, September 2016, Elsevier

    Tommaso Giani, Wright Nichols

  22. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria

    Article • Letters in Applied Microbiology, July 2016, Oxford University Press (OUP)

    Wright Nichols

  23. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations

    Article • Journal of Antimicrobial Chemotherapy, July 2016, Oxford University Press (OUP)

    Wright Nichols

  24. Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam

    Article • Antimicrobial Agents and Chemotherapy, December 2015, ASM Journals

    Dr Jean-Marie PAGES, Wright Nichols

  25. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases

    Article • Diagnostic Microbiology and Infectious Disease, May 2015, Elsevier

    Dr Michael R Jacobs, Wright Nichols

  26. How teams of scientists work to discover new medically-useful antibacterial agents

    Article • January 2015, Elsevier

    Wright Nichols

  27. In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

    Article • Antimicrobial Agents and Chemotherapy, December 2014, ASM Journals

    Dr. Karen Bush, Wright Nichols

  28. Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

    Article • Antimicrobial Agents and Chemotherapy, December 2013, ASM Journals

    Wright Nichols

  29. How foreign compounds like antibiotics get into bacteria

    Article • November 2011, Springer Science + Business Media

    Wright Nichols

  30. Microbiology On-a-Chip

    Article • January 2000, Springer Science + Business Media

    Wright Nichols

  31. Sequence analysis of the L1 metallo-β-lactamase from Xanthomonas maltophilia

    Article • Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, June 1994, Elsevier

    Wright Nichols

  32. Outer membrane permeability and porin proteins of Yersinia enterocolitica

    Article • FEMS Microbiology Letters, August 1990, Oxford University Press (OUP)

    Wright Nichols

  33. The Penetration of Antibiotics into Aggregates of Mucoid and Non-mucoid Pseudomonas aeruginosa

    Article • Microbiology, May 1989, Society for General Microbiology

    Wright Nichols

  34. Sonication can reduce β-lactamase activity

    Article • Journal of Antimicrobial Chemotherapy, January 1989, Oxford University Press (OUP)

    Wright Nichols

  35. Inhibition of tobramycin diffusion by binding to alginate.

    Article • Antimicrobial Agents and Chemotherapy, April 1988, ASM Journals

    Wright Nichols

  36. Bioenergetics of dihydrostreptomycin transport byEscherichia coli

    Article • FEBS Letters, February 1988, Wiley

    Wright Nichols

  37. On the mechanism of translocation of dihydrostreptomycin across the bacterial cytoplasmic membrane

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Bioenergetics, January 1987, Elsevier

    Wright Nichols

  38. Respiration-dependent uptake of dihydrostreptomycin by Escherichia coli. Its irreversible nature and lack of evidence for a uniport process

    Article • Biochemical Journal, June 1985, Portland Press Ltd.

    Wright Nichols

  39. Irreversible uptake of dihydrostreptomycin by Escherichia coli K12

    Article • Biochemical Society Transactions, April 1984, Portland Press Ltd.

    Wright Nichols

  40. THE PENETRATION OF ANTIBIOTICS THROUGH SODIUM ALGINATE AND THROUGH THE EXOPOLYSACCHARIDE OF A MUCOID STRAIN OF PSEUDOMONAS AERUGINOSA

    Article • The Lancet, September 1981, Elsevier

    Wright Nichols

  41. INHIBITORS OF FIREFLY LUCIFERASE IN CLINICAL URINE SPECIMENS

    Article • January 1981, Elsevier

    Wright Nichols

  42. The preparation of tightly coupled membrane vesicles from Paracoccus denitrificans

    Article • Analytical Biochemistry, June 1978, Elsevier

    Wright Nichols